{
    "nctId": "NCT03164486",
    "briefTitle": "First-in-Human Positron Emission Tomography Study Using the 18F-\u03b1v\u03b26-Binding-Peptide",
    "officialTitle": "First-in-Human Positron Emission Tomography Study Using the 18F-\u03b1v\u03b26-Binding-Peptide",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Metastatic Malignant Neoplasm in the Breast, Metastatic Malignant Neoplasm in the Colon, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Rectum, Pancreatic Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 27,
    "primaryOutcomeMeasure": "Assessment of safe administration of 18F-\u03b1v\u03b26-BP",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0-1\n* Will sign the Institutional Review Board (IRB)-approved consent form\n* Able to remain motionless for up to 30-60 minutes per scan\n\nExclusion Criteria:\n\n* Creatinine \\> 2 x upper limit of normal\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \\> 2 x upper limit of normal\n* Life expectancy \\< 3 months (mo)\n* Women who are pregnant or breast-feeding\n* Patients who cannot undergo PET/compute tomography (CT) scanning\n* Lack of availability for follow-up assessments\n* Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}